Furthermore, as stated earlier, the FIDELIO-DKD and FIGARO-DKD trials demonstrated a significant benefit (driven in part by a reduction in HF hospitalizations) of finerenone in patients with T2DM and CKD, highlighting the prognostic importance of albuminuria and the therapeutic relevance of targeting mineralocorticoid receptor overactivation [58,90]. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.